Second, TRPA1 drug blockade also reduced dacarbazine-induced nociception in a melanoma tumor-associated pain model, suggesting that this receptor may be a pharmacological agent for chemotherapy-induced pain syndrome in cancer patients receiving dacarbazine antitumor therapy (Brusco et al. 2020). Here, TRPA1 is linked to cancer.